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Background: The purpose of the current study was to analyze risk factors, clinical features, and treatment
outcomes in patients with endogenous fungal endophthalmitis with yeast and mold infections. For this
retrospective consecutive case series, microbiologic and clinical records were reviewed to identify all patients with
intraocular culture-proven endogenous fungal endophthalmitis treated at a single institution between January 1,
1990 and December 31, 2011.
Results: Sixty-seven eyes of 53 patients were identified; 51 eyes of 39 patients had positive cultures for yeast and
16 eyes of 14 patients had positive cultures for molds. Patients with molds as a causative organism had significantly
shorter duration of symptoms prior to diagnosis (molds 3.8 days, yeast 21.0 days, p = 0.002), were more likely to be
receiving iatrogenic immunosuppression (molds 57.1%, yeast 7.7%, p = 0.001), have a history of whole-organ
transplantation (molds 35.7%, yeast 2.6%, p = 0.001), and were more likely to have hypopyon at the time of
diagnosis (molds 37.5%, yeast 6.0%, p = 0.001). Patients with endogenous endophthalmitis caused by molds had
significantly worse visual acuity at the time of diagnosis (logMAR visual acuity molds 1.80, yeast 1.15, p = 0.008) and
at final visit (logMAR visual acuity molds 1.97, yeast 1.05, p = 0.005) compared to those patients with yeast as a
causative organism. There was no significant difference in the rate of retinal detachment between the two groups
(mold 12.5%, yeast 30.6%, p = 0.201). Patients with cultures positive for mold were significantly more likely to
undergo enucleation (molds 25.0%, yeast 0%, p < 0.001).
Conclusions: Systemic risk factors for patients with endogenous fungal endophthalmitis caused by molds were
iatrogenic immunosuppression and a history of whole-organ transplantation. Shorter duration of symptoms before
diagnosis and higher rates of hypopyon occurred in mold cases. While endogenous fungal endophthalmitis is
generally associated with poor visual acuity outcomes, infection with mold species was associated with worse visual
acuity on presentation and on final follow-up than infection with yeast species. Enucleation rates were much higher
in mold cases.
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Endogenous fungal endophthalmitis is a serious ocular
condition associated with poor visual outcomes [1-3].
Most patients with this entity have predisposing systemic
risk factors, although it may occur rarely in healthy im-
munocompetent individuals [4,5]. In previous reports, the
most common organism causing endogenous fungal* Correspondence: jsridhar@med.miami.edu
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in any medium, provided the original work is pendophthalmitis was the yeast species Candida albicans,
followed by molds such as Aspergillus species [6-8].
The purpose of the current study was to analyze and re-
port differences in risk factors, clinical presentation, and
treatment outcomes between patients with endogenous
fungal endophthalmitis caused by yeast and patients with
endogenous fungal endophthalmitis caused by molds.
Methods
The Institutional Review Board approval was obtained
from the University of Miami Miller, School of Medicinean Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.














Figure 1 Endogenous fungal endophthalmitis caused by yeast.
A 34-year-old HIV-positive woman presented with 20/25 vision in the
left eye. Fundoscopic examination demonstrated a focal yellow retinal
lesion inferotemporal to the optic nerve in the left eye. The patient
underwent vitreous paracentesis in the left eye with cultures growing
Candida albicans. The patient received three intravitreal injections of
amphotericin B. Visual acuity on final follow-up was 20/25.
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Subjects. A search of the ocular microbiology depart-
ment database was performed to identify all patients with
positive vitreous tap and vitrectomy specimen cultures for
fungal species between January 1, 1990 and December 31,
2011. Medical records were subsequently reviewed to
include those patients with a clinical course consistent
with endogenous fungal endophthalmitis. The included
patients’ medical records were reviewed for presenting
clinical features, relevant patient past medical history, and
treatment outcomes. Some of the patients included in this
study were previously reported without statistical compari-
son in a series published by Lingappan et al. [3]. Fungal
cultures and identification were performed as previously
described in that series [9,10].
Fungal culture results were considered positive when
there was growth of the same organism on two or more
solid media at the inoculation site, or when the organism
grew on one culture media and was noted on a stained
smear (gram, Giemsa, or Gomori methenamine silver)
[11]. Treatment and management decisions were made by
the individual treating physicians without a predefined
study protocol.
For statistical analysis, the Snellen visual acuity (VA)
was converted to logarithm of minimal angle of reso-
lution (logMAR) equivalents and VA of count fingers,
hand motion, light perception, and no light perception
were assigned logMAR values of 1.85, 2.3, 2.7, and 3.0,
respectively, as previously described [12,13]. The logMAR
VA is presented as mean ± standard deviation. Presenting
and final VA was compared between the yeast and mold
group using a Student’s t test. The difference in presenting
VA and last recorded VA was also compared between the
two groups using a Student’s t test. A Pearson chi-square
test was used to compare presenting symptoms/signs, risk
factors, initial treatments, enucleations, and complication
between the two groups. A p value of < 0.05 was consid-
ered statistically significant.
Results
Over the 22-year study period, 67 eyes of 53 patients were
identified as having positive cultures and a clinical diagnosis
of endogenous fungal endophthalmitis. Of these, 51 eyes of
39 patients had yeast species and 16 eyes of 14 patients had
mold species (Table 1). The mean age of included patients
was 50.0 years (range 3 months to 92 years). Mean follow-
up was 16.4 months for yeast cases (range 0.25 to 180
months) and 9.6 months (range 0.25 to 34 months). Repre-
sentative cases are shown in Figures 1 and 2.
A comparison of patient risk factors between the two
groups is shown in Table 2. Patients with infection with
mold species were significantly more likely to be receiving
iatrogenic immunosuppression, including chemotherapy,
(molds 57.1%, yeast 7.7%, p = 0.001) and have a history ofwhole-organ transplantation, including cardiac and liver
transplantation (molds 35.7%, yeast 2.6%, p = 0.001). Posi-
tive mold cultures were also significantly associated with
having an indwelling venous line or catheter (p = 0.010).
There was no significant difference between the patient
groups in recent hospitalization (p = 0.872) or positive
systemic cultures (molds 14.3%, yeast 25.6%, p = 0.384).
Patients with endogenous endophthalmitis caused by
molds were diagnosed significantly closer to onset of symp-
toms (Table 3, p = 0.002). While there was no significant
difference between the groups in terms of the type of intra-
ocular inflammation noted by the initial treating physician,
patients with positive mold cultures were significantly
Figure 2 Endogenous fungal endophthalmitis caused by mold. A 39-year-old man with history of IV drug use presented with redness and
HM vision in the right eye. Fundus examination revealed vitritis and retinitis centered in the macula (above left). The patient underwent pars
plana vitrectomy with injection of intravitreal amphotericin B. Pars plana vitrectomy specimen was positive for Aspergillus glaucus. Visual acuity on
final follow-up was 4/200 (above right).
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(molds 37.5%, yeast 6.0%, p = 0.002). Information concern-
ing symptoms and signs was not available for one infant
patient.
Patients with endogenous endophthalmitis caused by
molds were significantly more likely to receive systemic an-
tifungal therapy (Table 4, p = 0.035), specifically intravenous
antifungal therapy (p = 0.011). Systemic intravenous agents
included amphotericin B, fluconazole, ketoconazole, and
voriconazole. Systemic oral agents included voriconazole
and fluconazole. There was no significant difference be-
tween the two groups in whether a patient underwent a vit-
reous tap (p = 0.536) or pars plana vitrectomy (molds 50%,
yeast 56.9%, p = 0.630) as the initial management strategy.
Intravitreal antifungal agents used included amphotericin B
(5 μg/0.1 ml) and voriconazole (50 μg/0.1 ml). There was
no significant difference between the two groups in numberTable 2 Systemic risk factors for endogenous
fungal endophthalmitis
Risk factor Yeast (%) Mold (%) p value
Recent hospitalization 26/39 (66.7%) 9/14 (64.3%) 0.872
Recent surgery 12/39 (30.8%) 4/14 (28.6%) 0.878
Any immunocompromise 20/39 (51.3%) 9/14 (64.3%) 0.402
Iatrogenic 3/39 (7.7%) 8/14 (57.1%) 0.001
Diabetes mellitus 7/39 (17.9%) 4/14 (28.6%) 0.589
Cancer 9/39 (23.1%) 3/14 (21.4%) 0.899
HIV 3/39 (7.7%) 0/14 (0.0%) 0.285
Any IV/IVDU/catheter/HD 16/39 (41.0%) 10/14 (71.4%) 0.010
IVDU 6/39 (15.4%) 4/14 (28.6%) 0.279
Indwelling catheter 3/39 (7.7%) 0/14 (0.0%) 0.285
History of transplant 1/39 (2.6%) 5/14 (35.7%) 0.002
Positive systemic culturea 10/39 (25.6%) 2/14 (14.3%) 0.384
HIV, human immunodeficiency virus; IV, intravenous line; IVDU, intravenous
drug use; HD, hemodialysis port; Pearson chi-square test used for statistical
analysis. a Positive systemic cultures for yeast included blood (7), urine (2), and
cerebrospinal fluid (1). Positive systemic cultures for mold included sputum (2).of eyes requiring multiple intravitreal injections of antifun-
gals (molds 50%, yeast 33%, p = 0.229).
Treatment outcomes are summarized in Table 5. Pa-
tients with endogenous endophthalmitis caused by molds
had significantly worse visual acuity on presentation (p =
0.008) and on final follow-up (p = 0.005). There was no
significant difference between the groups in change in vis-
ual acuity from presentation to final follow-up (p = 0.384)
and there was no significant difference in the rate of ret-
inal detachment between the groups (p = 0.201). Patients
with endogenous endophthalmitis caused by molds under-
went enucleation more frequently (molds 25%, yeast 0%,
p < 0.001). There was no significant difference between
mold and yeast subgroups in patient mortality (mold
7.1%, yeast 5.1%, p = 0.780).
Discussion
The clinical diagnosis of endogenous fungal endophthal-
mitis has been well described in previous case series and
case reports [1,6,14,15]. While there have been descriptions
of the differences between patients with yeast infection and
patients with mold infection, no large head-to-head statis-
tical comparisons of culture-proven cases have been previ-
ously reported [16].
In the current study, endogenous endophthalmitis caused
by molds, consisting mainly of Aspergillus species, was fre-
quently associated with history of iatrogenic immunosup-
pression and organ transplantation. In models of invasive
aspergillosis impaired neutrophil function has been shown
to play a major role in the development of infection, and
prolonged steroid use or other immunosuppression may
depress neutrophil function [17]. Riddell et al. previously
reported in a review of the literature that 43% of patients
with endogenous Aspergillus endophthalmitis had received
prior treatment with corticosteroids [7]. The current study
also demonstrated a significantly shorter duration of symp-
toms for patients presenting with endogenous endoph-
thalmitis caused by molds. Infected eyes were also more
Table 3 Clinical features of endogenous fungal endophthalmitis
Clinical feature Yeast Mold p value
Bilateral 12/39 (30.8%) 2/14 (14.3%) 0.230
Duration of symptoms (mean days ± SD) 21.0 ± 32.9 3.8 ± 5.4 0.002
Hypopyon 3/50 (6.0%) 6/16 (37.5%) 0.001
Diffuse anterior and posterior inflammation 33/50 (66.0%) 11/16 (68.8%) 0.839
Anterior inflammation only 2/50 (4.0%) 1/16 (6.3%) 0.707
Posterior inflammation only 15/50 (30.0%) 4/16 (25.0%) 0.701
SD, standard deviation; Pearson chi-square test used for statistical analysis. Note: Information concerning clinical features was not available for one infant patient
with endogenous endophthalmitis caused by yeast.
Table 5 Treatment outcomes of endogenous
fungal endophthalmitis
Treatment outcome Yeast Mold p value
Visual Acuity (VA) n = 39 (51 eyes) n = 14 (16 eyes)
Presenting mean 1.15 (± 0.78) 1.80 (± 0.80) 0.008
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histopathologic specimens to prominently invade through
blood vessel walls in the choroid leading to necrosis and
more rapid involvement of the vitreous [16]. As such, infec-
tion with more virulent mold organisms has been shown in
the literature to correlate with worse visual acuity outcomes
and higher rates of enucleation, as it did in the current
study [1,6]. Given the fulminant course of mold infections,
patients often require systemic antifungal therapy, as dem-
onstrated in the current study.
In contrast, patients with endogenous endophthalmitis
caused by yeast presented more indolently and with bet-
ter visual acuities, matching descriptions in the literature
[18]. Shen et al. previously reported 29 eyes with en-
dogenous fungal endophthalmitis, and none of the mold
cases achieving final visual acuity of 20/200 or better; in
contrast, 53% of Candida cases achieved that outcome
[19]. Due to less clear patient histories and nonspecific
examination findings mimicking uveitis, misdiagnosis of
Candida endophthalmitis has been reported to approach
50% [19]. Thus, it is imperative to investigate for risk fac-
tors such as recent hospitalization, recent surgery, and
intravenous drug use and entertain a diagnosis of fungal
endophthalmitis when approaching the uveitis patient with
progressive signs and symptoms.
Retinal detachment was a frequent event in the follow-up
course for patients in both groups. Retinal detachment is
associated with poor visual outcome and is a potential
complication of vitrectomy for endophthalmitis [20,21].Table 4 Initial management strategies for endogenous
fungal endophthalmitis
Initial treatment Yeast (%) Mold (%) p value
Local ocular therapy 41/51 (80.4%) 13/16 (81.3%) 0.940
Tap 12/51 (23.5%) 5/16 (31.3%) 0.536
PPV 29/51 (56.9%) 8/16 (50.0%) 0.630
Systemic treatment 30/51 (58.8%) 14/16 (87.5%) 0.035
Oral 16/51 (31.4%) 4/16 (25.0%) 0.627
Intravenous 14/51 (27.5%) 10/16 (62.5%) 0.011
Tap: diagnostic vitreous tap; PPV, pars plana vitrectomy with culture; Pearson
chi-square test used for statistical analysis.One proposed mechanism is post-operative peripheral vit-
reous contraction inducing retinal breaks [3]. However, in
the Endophthalmitis Vitrectomy Study, there was no signifi-
cant difference in the rate of retinal detachment between
patients undergoing needle tap and vitrectomy biopsy [22].
It was recently postulated that early vitrectomy in endogen-
ous endophthalmitis caused by yeast might reduce the inci-
dence of retinal detachment [23]. Sallam et al. reviewed 44
eyes with Candida endophthalmitis and reported that eyes
that underwent vitrectomy within a week of presentation
resulted in a retinal detachment rate of 8% versus 41% in
those eyes with delayed vitrectomy.
Pars plana vitrectomy was frequently utilized as the initial
management strategy for patients in both groups of the
current study. It has been suggested that early vitrectomy is
preferable for these patients since vitreous paracentesis may
not obtain an adequate vitreous sample of the localized in-
fection. Endogenous fungal endophthalmitis classically be-
gins with choroidal seeding and eventually invades the
vitreous cavity [16]. In the current series, the most common
isolate was C. albicans followed by Aspergillus fumigatus.logMAR VA (+/− SD)
Final mean logMAR 1.05 (± 1.01) 1.97 (± 1.18) 0.005
VA (± SD)
Change mean 0.11 (± 0.98) −0.17 (± 1.24) 0.384
logMAR VA (± SD)
Multiple IVF injections 17/51 (33.3%) 8/16 (50.0%) 0.229
Retinal detachment 15/49 (30.6%) 2/16 (12.5%) 0.201
Cataract 11/49 (22.4%) 1/16 (6.25%) 0.147
Enucleation 0/51 (0.0%) 4/16 (25.0%) < 0.001
SD, standard deviation; IVF, intravitreal antifungal; Student’s t test used for
statistical analysis of presenting, final, and change in VA; Pearson chi-square
test used for statistical analysis of retinal detachment, cataract formation, and
enucleation rate.
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[24,25]. Of note, polymerase chain reaction (PCR) testing
has shown to be more rapid and sensitive than traditional
mycology cultures in diagnosing fungal endophthalmitis
and is now employed at many medical centers [26].
In patients with a suspected infection, a diagnostic vi-
trectomy may be considered initially. Intravitreal therapy
can be specifically targeted once appropriate stains and
culture results are obtained. Oral antifungal therapy is
also considered, usually fluconazole or voriconazole. De-
pending on the clinical response to initial treatment,
intravitreal injections can be given until the infectious
process resolves. Patients can be monitored closely for
retinal detachment. Although there are early reports pro-
posing the use of intravitreal corticosteroids as an adjunct,
there is no well-designed prospective, comparative trial
addressing this point and as such, intravitreal steroids are
not recommended given the risk of inhibiting the host im-
mune response [27,28].
The current study is limited by its retrospective design
as well its relatively small number of patients. Rapid and
sensitive PCR testing was not available for clinical use at
our institution during the entire study period. Patients
had quite variable follow-up and data could be missing
from the chart review. Patients were identified based on
positive intraocular cultures and thus cases of presumed
endogenous endophthalmitis in which cultures were not
obtained may have been excluded. In spite of these limita-
tions, this study demonstrates and reinforces key differences
between endogenous endophthalmitis caused by molds
compared to yeasts.
Conclusions
Patients with endogenous endophthalmitis caused by
molds were more likely to be receiving iatrogenic im-
munosuppression and have a history of whole-organ
transplantation than those patients with endogenous en-
dophthalmitis caused by yeast. Shorter duration of symp-
toms before diagnosis and higher rates of hypopyon
occurred in mold cases. While endogenous fungal en-
dophthalmitis is generally associated with poor visual acu-
ity outcomes, infection with mold species was associated
with worse visual acuity on presentation and on final
follow-up than infection with yeast species. Enucleation
rates were much higher in mold cases.
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